Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1997 Jan;76(1):73–75. doi: 10.1136/adc.76.1.73

Biphosphonates

J Allgrove 1
PMCID: PMC1717046  PMID: 9059169

Full Text

The Full Text of this article is available as a PDF (60.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassett C. A., Donath A., Macagno F., Preisig R., Fleisch H., Francis M. D. Diphosphonates in the treatment of myositis ossificans. Lancet. 1969 Oct 18;2(7625):845–845. doi: 10.1016/s0140-6736(69)92293-4. [DOI] [PubMed] [Google Scholar]
  2. Bembi B., Agosti E., Boehm P., Nassimbeni G., Zanatta M., Vidoni L. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr. 1994 Jan;83(1):122–124. doi: 10.1111/j.1651-2227.1994.tb12968.x. [DOI] [PubMed] [Google Scholar]
  3. Bishop N. J., Williams D. M., Compston J. C., Stirling D. M., Prentice A. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol. 1995 Apr;89(4):927–928. doi: 10.1111/j.1365-2141.1995.tb08441.x. [DOI] [PubMed] [Google Scholar]
  4. Boudailliez B. R., Pautard B. J., Sebert J. L., Kremp O., Piussan C. X. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol. 1990 Sep;4(5):510–511. doi: 10.1007/BF00869834. [DOI] [PubMed] [Google Scholar]
  5. Cassinelli H. R., Mautalen C. A., Heinrich J. J., Miglietta A., Bergada C. Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone Miner. 1992 Nov;19(2):175–184. doi: 10.1016/0169-6009(92)90924-3. [DOI] [PubMed] [Google Scholar]
  6. Chines A., Petersen D. J., Schranck F. W., Whyte M. P. Hypercalciuria in children severely affected with osteogenesis imperfecta. J Pediatr. 1991 Jul;119(1 Pt 1):51–57. doi: 10.1016/s0022-3476(05)81038-8. [DOI] [PubMed] [Google Scholar]
  7. Devogelaer J. P., Malghem J., Maldague B., Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360–363. doi: 10.1007/BF00350961. [DOI] [PubMed] [Google Scholar]
  8. Harinck H. I., Bijvoet O. L., van der Meer J. W., Jones B., Onvlee G. J. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate. Lancet. 1984 Sep 1;2(8401):513–513. doi: 10.1016/s0140-6736(84)92579-0. [DOI] [PubMed] [Google Scholar]
  9. Hoekman K., Papapoulos S. E., Peters A. C., Bijvoet O. L. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab. 1985 Nov;61(5):952–956. doi: 10.1210/jcem-61-5-952. [DOI] [PubMed] [Google Scholar]
  10. Huaux J. P., Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop. 1988 Jan-Feb;8(1):71–72. doi: 10.1097/01241398-198801000-00017. [DOI] [PubMed] [Google Scholar]
  11. Lepore L., Pennesi M., Barbi E., Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991 Jan-Feb;9 (Suppl 6):33–35. [PubMed] [Google Scholar]
  12. Liens D., Delmas P. D., Meunier P. J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994 Apr 16;343(8903):953–954. doi: 10.1016/s0140-6736(94)90069-8. [DOI] [PubMed] [Google Scholar]
  13. Macarol V., Fraunfelder F. T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994 Aug 15;118(2):220–224. doi: 10.1016/s0002-9394(14)72902-2. [DOI] [PubMed] [Google Scholar]
  14. McIntyre H. D., Cameron D. P., Urquhart S. M., Davies W. E. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J. 1989 Apr;65(762):244–246. doi: 10.1136/pgmj.65.762.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meradji M., de Villeneuve V. H., Huber J., de Bruijn W. C., Pearse R. G. Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. J Pediatr. 1978 Mar;92(3):401–405. doi: 10.1016/s0022-3476(78)80427-2. [DOI] [PubMed] [Google Scholar]
  16. Profumo R. J., Reese J. C., Foy T. M., Garibaldi L. R., Kane R. E. Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation. 1994 Jan;57(2):301–303. [PubMed] [Google Scholar]
  17. Rawlinson P. S., Green R. H., Coggins A. M., Boyle I. T., Gibson B. E. Malignant osteopetrosis: hypercalcaemia after bone marrow transplantation. Arch Dis Child. 1991 May;66(5):638–639. doi: 10.1136/adc.66.5.638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rogers J. G., Dorst J. P., Geho W. B. Use and complications of high-dose disodium etidronate therapy in fibrodysplasia ossificans progressiva. J Pediatr. 1977 Dec;91(6):1011–1014. doi: 10.1016/s0022-3476(77)80918-9. [DOI] [PubMed] [Google Scholar]
  19. Samuel R., Katz K., Papapoulos S. E., Yosipovitch Z., Zaizov R., Liberman U. A. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics. 1994 Sep;94(3):385–389. [PubMed] [Google Scholar]
  20. Shaw N. J., White C. P., Fraser W. D., Rosenbloom L. Osteopenia in cerebral palsy. Arch Dis Child. 1994 Sep;71(3):235–238. doi: 10.1136/adc.71.3.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. Br J Rheumatol. 1995 Jan;34(1):68–77. doi: 10.1093/rheumatology/34.1.68. [DOI] [PubMed] [Google Scholar]
  22. Thiaville A., Smets A., Clercx A., Perlmutter N. Idiopathic infantile arterial calcification: a surviving patient with renal artery stenosis. Pediatr Radiol. 1994;24(7):506–508. doi: 10.1007/BF02015014. [DOI] [PubMed] [Google Scholar]
  23. Tsuchimoto M., Azuma Y., Higuchi O., Sugimoto I., Hirata N., Kiyoki M., Yamamoto I. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol. 1994 Sep;66(1):25–33. doi: 10.1254/jjp.66.25. [DOI] [PubMed] [Google Scholar]
  24. Varache N., Audran M., Clochon P., Lortholary A., Bouachour G., Alquier P., Basle M. F. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Clin Rheumatol. 1991 Sep;10(3):328–332. doi: 10.1007/BF02208702. [DOI] [PubMed] [Google Scholar]
  25. Vera J., Lucaya J., Garcia Conesa J. A., Aso C., Balaguer A. Idiopathic infantile arterial calcification: unusual features. Pediatr Radiol. 1990;20(8):585–587. doi: 10.1007/BF02129060. [DOI] [PubMed] [Google Scholar]
  26. Yamaguchi K., Grant J., Noble-Jamieson G., Jamieson N., Barnes N. D., Compston J. E. Hypercalcaemia in primary oxalosis: role of increased bone resorption and effects of treatment with pamidronate. Bone. 1995 Jan;16(1):61–67. [PubMed] [Google Scholar]
  27. van Persijn van Meerten E. L., Kroon H. M., Papapoulos S. E. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992 Jul;184(1):249–254. doi: 10.1148/radiology.184.1.1609087. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES